NasdaqGM:CRSPBiotechs
CRISPR Therapeutics (NasdaqGM:CRSP) Announces Promising Data From Cardiovascular Disease Programs
CRISPR Therapeutics (NasdaqGM:CRSP) recently announced updates on its in vivo cardiovascular disease programs, marking significant progress in trials for CTX310™ and CTX320™. The company's shares surged 29% over the past month, potentially influenced by these developments, suggesting optimism around its clinical pipeline's potential to address high-risk cardiovascular conditions. Additionally, executive and bylaw changes, such as the addition of Dr. Briggs W. Morrison to the Board's...